Surgical Robotics in 2026: da Vinci 5, Hugo, Ottava, Mako, Versius

Surgical robotics in 2026 finally looks like a market, not a monopoly. Intuitive Surgical’s da Vinci was effectively unchallenged for two decades; by 2026 Medtronic, Johnson & Johnson, Stryker, CMR Surgical, and a handful of newer entrants are all in the operating room. The market is still small relative to global surgery volume, but the trajectory is steeper than it has ever been, and the AI-assisted surgery story is becoming real.

We don’t manufacture surgical robots, but we do build the hospital data platforms and integration layers that surround them. So here’s the 2026 read on the vendors, the AI roadmap, and where the technology actually changes patient outcomes.

Intuitive Surgical and the da Vinci 5#

Intuitive Surgical is the incumbent and still owns the lion’s share of installed base. By 2025 the company had over 9,500 da Vinci systems installed globally and was approaching 15 million cumulative procedures. The da Vinci 5, launched in 2024, is the first major platform refresh in nearly a decade.

Da Vinci 5 brings genuine engineering changes: a more powerful processor (10,000x compute of da Vinci Xi according to Intuitive), force feedback at the surgeon’s console, a refined surgeon ergonomic design, and integrated case-data analytics. The force feedback is the most surgically meaningful addition — previous generations gave the surgeon visual cues only, with no tactile sense of tissue resistance.

What da Vinci 5 doesn’t yet do: full AI-driven autonomy. Every motion is still surgeon-controlled. The AI work is in the analytics and case-review layer, not in the live procedure.

Intuitive’s moat in 2026 is still procedural: 25 years of accumulated surgical procedure data, FDA clearances, surgeon training programs, and a service network. New entrants compete on price, ergonomics, or single-port designs — none yet matches the breadth.

Medtronic Hugo: the open-system challenger#

Medtronic’s Hugo RAS (Robotic-Assisted Surgery) system launched commercially outside the US in 2021 and received expanded approvals through 2024-2025. US FDA clearance for specific procedures came through more slowly than Medtronic hoped, but by 2026 Hugo has clearance pathways underway in multiple specialties.

Hugo’s differentiated bet is modularity and open instrument compatibility — the arms are individually mobile (not all on one boom like da Vinci), and Medtronic aims to be more flexible about third-party instruments. The clinical comparisons against da Vinci have been mixed but acceptable; the price advantage matters for hospitals that couldn’t afford a da Vinci.

In 2026 Hugo is the most credible challenger by installed-base trajectory outside the US. Inside the US, regulatory pace remains the rate limiter.

J&J Ottava: delayed but credible#

Johnson & Johnson’s Ottava platform, in development since the acquisitions of Auris Health and Verb Surgical, has slipped its launch timeline multiple times. As of 2026, Ottava is in late-stage development with first clinical use expected within 2026-2027 outside the US.

The technical story: four arms mounted to the operating table itself, modular sensor integration, integration with J&J’s broader surgical portfolio (Ethicon staplers, advanced energy, monocle visualization). When Ottava launches at scale, J&J has the global hospital relationships and surgical product portfolio to compete seriously.

The 2026 read on Ottava: still a “wait and see,” but a serious threat to Intuitive’s moat when it does ship.

Stryker Mako: the orthopedic specialist#

Stryker’s Mako system is a different category — orthopedic, focused on knee, hip, and shoulder replacement procedures. Where da Vinci dominates soft-tissue surgery, Mako dominates joint replacement. Stryker’s installed base has grown rapidly through 2020-2025, and orthopedic surgeons report Mako-assisted procedures produce more consistent implant alignment.

Mako’s AI story is preoperative: CT-based 3D planning of the implant position, with the robot enforcing the plan intraoperatively. The robot doesn’t operate autonomously; it constrains the surgeon’s instrument to the pre-planned cuts. That’s a sensible safety boundary and the clinical evidence supports the approach.

Stryker’s competition in orthopedic robotics: Zimmer Biomet’s ROSA, Smith+Nephew’s CORI, J&J Medical Devices’ VELYS. Each has installed base in specific markets, but Mako leads.

CMR Surgical Versius: the UK challenger#

CMR Surgical, founded in Cambridge UK, makes Versius — a portable, modular surgical robot designed to be moved between operating rooms more easily than da Vinci. CMR was valued at $3B in its 2021 funding round, and by 2026 has installations across UK NHS hospitals, India, Europe, and select Latin American markets.

Versius’s pitch: lower capital cost, more hospital flexibility, easier deployment in mid-tier facilities that can’t justify a da Vinci. The clinical performance is broadly acceptable across colorectal, gynecology, and urology procedures.

In 2026 Versius is the credible global alternative to da Vinci outside the US, particularly in cost-sensitive markets where Intuitive’s pricing is prohibitive.

Moon Surgical Maestro and the laparoscopic-assist category#

Moon Surgical, founded in Paris, takes a different angle: rather than replace the surgeon’s hands as da Vinci does, Maestro is a robotic assistant that holds and stabilises laparoscopic instruments under surgeon control. It’s a lower-cost, lower-disruption entry into the OR — the surgeon still does the surgery, but with robotic assistance.

Moon raised meaningful funding in 2024 and started clinical use in Europe. The category bet: most hospitals can’t afford full surgical robots, but many can afford a robotic assistant. If Moon’s category proves out, it expands the addressable market dramatically.

Vicarious Surgical and the lessons of delay#

Vicarious Surgical, once a high-profile SPAC-era company with a unique single-port humanoid-like surgical robot, has struggled. The platform was technically ambitious but commercial deployment slipped repeatedly. The company restructured in 2024 and continues to develop, but is now well behind the field.

The lesson: surgical robotics is unforgiving on regulatory timelines. A clever design that takes three extra years to clear is a clever design that loses the market.

The AI-assisted surgery roadmap#

The 2026 AI-in-surgery story is less dramatic than the press suggests, and more meaningful than the skeptics suggest. The honest layers:

• Preoperative planning — CT and MRI integration, 3D anatomical modeling, surgical plan generation. Real and increasingly capable in 2026.
• Intraoperative visualization — vision overlays showing tissue type, vessel locations, tumor margins. Real, with FDA-cleared examples in specific procedures.
• Skill assessment and training — AI scoring of surgeon technique on simulators and recorded cases. Real and increasingly used in training programs.
• Workflow analytics — AI analysis of recorded cases for time-on-step, error events, comparative outcomes. Real in research; spreading to operational hospital use.
• Semi-autonomous task completion — robot completes a sub-task (e.g., suturing) under surgeon supervision. Research stage with early clinical demonstrations; not standard practice.
• Fully autonomous surgery — not in 2026, not in 2027, and probably not in 2030 except for very constrained procedures.

The pattern: AI is augmenting the surgeon’s information, planning, and review, not replacing the surgeon’s hands. That’s both the safe regulatory path and the clinically appropriate one for the foreseeable future.

Integration with the hospital data platform#

Surgical robots produce a tremendous amount of data per case: video, instrument telemetry, vital signs integration, console interactions. In 2026 most hospitals capture only a sliver of this systematically. The hospitals that build a data lake covering surgical telemetry are positioning themselves for AI-driven outcome improvement; the rest are leaving signal on the floor.

This is where our work shows up. For hospital management platforms we deploy, the integration with surgical robotics telemetry — and the broader OR ecosystem (anesthesia, imaging, anesthesia information management) — is a meaningful part of the data architecture. Robot data joined with patient outcomes is the substrate for the next decade of surgical AI.

What we tell hospital systems#

Hospital systems sizing surgical robotics in 2026 should think about three things:

1. Multi-vendor strategy — the days of “buy a da Vinci and that’s the robotics program” are ending. Mako for orthopedics, da Vinci or Hugo for soft tissue, Versius for cost-sensitive sites. Plan for heterogeneity.
2. Data capture from day one — every case generates data; that data is valuable; capture systematically.
3. AI-assist over AI-autonomy — the safe, regulator-friendly, clinically appropriate frame is augmentation, not replacement. Vendors that pitch otherwise should be discounted.

Related reading#

• Industrial robotics in 2026: FANUC, ABB, KUKA, and the AI shift
• Humanoid robots: Figure, Tesla, Apptronik, and foundation models
• AI in healthcare: clinical workflow, imaging, and regulatory posture

---

Surgical robotics in 2026 is competitive, AI-augmented, and finally past the single-vendor era. If you’re sizing a hospital data platform that has to integrate surgical telemetry, imaging, EMR, and outcomes data, our hospital management work builds that data spine. Tell us about the hospital.